Genetic deficiency of β2-containing nicotinic receptors attenuates brain injury in ischemic stroke

Neuroscience

Volumn 256, Issue , 2014, Pages 170-177

  Liu, Q ^a,b   Tang, Z ^a   Gan, Y ^a   Wu, W ^a   Kousari, A ^a   La Cava, A ^c   Shi, F D ^a,b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ischemic stroke; Middle cerebral artery occlusion; Neuroprotection; Nicotinic receptor; Oxygen glucose deprivation

Indexed keywords

CASPASE 3; DNA NUCLEOTIDYLEXOTRANSFERASE; GLUCOSE; GLUTAMIC ACID; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; OXYGEN; DIHYDRO BETA ERYTHROIDINE; LACTATE DEHYDROGENASE; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR BETA2;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CELL; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG MECHANISM; EXCITOTOXICITY; FUNCTIONAL ASSESSMENT; GENE DELETION; GENETIC DISORDER; MALE; MOUSE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TREATMENT OUTCOME; ACTION POTENTIAL; ANIMAL; ANOXIA; BRAIN CORTEX; BRAIN INJURIES; CELL CULTURE; CEREBRAL ARTERY DISEASE; COMPLICATION; CYTOLOGY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; TIME;

ACTION POTENTIALS; ANIMALS; ANOXIA; BRAIN INJURIES; CELLS, CULTURED; CEREBRAL CORTEX; DIHYDRO-BETA-ERYTHROIDINE; DISEASE MODELS, ANIMAL; GLUCOSE; INFARCTION, MIDDLE CEREBRAL ARTERY; L-LACTATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, KNOCKOUT; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 84888121555     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.10.049     Document Type: Article

References (39)

1. 2+-independent glutamatergic vesicle release through actin filament depolymerization in area CA1 of the hippocampus. J Physiol 2010, 588:1499-1514.
2. Bardutzky J., Meng X., Bouley J., Duong T.Q., Ratan R., Fisher M. Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model. J Cereb Blood Flow Metab 2005, 25:968-977.
3. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
4. Berger C., Schabitz W.R., Wolf M., Mueller H., Sommer C., Schwab S. Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke. Exp Neurol 2004, 185:305-312.
5. Bertrand N., Ishii H., Beley A., Spatz M. Biphasic striatal acetylcholine release during and after transient cerebral ischemia in gerbils. J Cereb Blood Flow Metab 1993, 13:789-795.
6. Bertrand N., Ishii H., Spatz M. Cerebral ischemia in young and adult gerbils: effects on cholinergic metabolism. Neurochem Int 1996, 28:293-297.
7. Broughton B.R., Reutens D.C., Sobey C.G. Apoptotic mechanisms after cerebral ischemia. Stroke 2009, 40:e331-339.
8. Cunningham C.S., McMahon L.R. The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in alpha4beta2 nicotinic receptor activation. Eur J Pharmacol 2011, 654:47-52.
9. Davalos A., Castillo J., Serena J., Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 1997, 28:708-710.
10. * nicotinic stimulation. Toxicol Sci 2011, 123:193-205.
11. Dickinson J.A., Kew J.N., Wonnacott S. Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol 2008, 74:348-359.
12. Duris K., Manaenko A., Suzuki H., Rolland W.B., Krafft P.R., Zhang J.H. Alpha7 nicotinic acetylcholine receptor agonist PNU-282987 attenuates early brain injury in a perforation model of subarachnoid hemorrhage in rats. Stroke 2011, 42:3530-3536.
13. Fan Y., Deng P., Wang Y.C., Lu H.C., Xu Z.C., Schulz P.E. Transient cerebral ischemia increases CA1 pyramidal neuron excitability. Exp Neurol 2008, 212:415-421.
14. Garduno J., Galindo-Charles L., Jimenez-Rodriguez J., Galarraga E., Tapia D., Mihailescu S., Hernandez-Lopez S. Presynaptic alpha4beta2 nicotinic acetylcholine receptors increase glutamate release and serotonin neuron excitability in the dorsal raphe nucleus. J Neurosci 2012, 32:15148-15157.
15. Ginsberg M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008, 55:363-389.
16. Hao J., Liu R., Piao W., Zhou Q., Vollmer T.L., Campagnolo D.I., Xiang R., La Cava A., Van Kaer L., Shi F.D. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010, 207:1907-1921.
17. He P., Liu Q., Wu J., Shen Y. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. FASEB J 2012, 26:334-345.
18. Hoyte L., Barber P.A., Buchan A.M., Hill M.D. The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med 2004, 4:131-136.
19. Kozhemyakin M., Rajasekaran K., Kapur J. Central cholinesterase inhibition enhances glutamatergic synaptic transmission. J Neurophysiol 2010, 103:1748-1757.
20. Krafft P.R., Altay O., Rolland W.B., Duris K., Lekic T., Tang J., Zhang J.H. Alpha7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3beta inhibition in a mouse model of intracerebral hemorrhage. Stroke 2012, 43:844-850.
21. Laudenbach V., Medja F., Zoli M., Rossi F.M., Evrard P., Changeux J.P., Gressens P. Selective activation of central subtypes of the nicotinic acetylcholine receptor has opposite effects on neonatal excitotoxic brain injuries. FASEB J 2002, 16:423-425.
22. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431-1568.
23. Liu Q., Huang Y., Xue F., Simard A., DeChon J., Li G., Zhang J., Lucero L., Wang M., Sierks M., Hu G., Chang Y., Lukas R.J., Wu J. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009, 29:918-929.
24. Mao Y., Yang G.Y., Zhou L.F., Stern J.D., Betz A.L. Focal cerebral ischemia in the mouse: description of a model and effects of permanent and temporary occlusion. Brain Res Mol Brain Res 1999, 63:366-370.
25. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., Craig C.R., Collins A.C., Damaj M.I., Donny E.C., Gardiner P.S., Grady S.R., Heberlein U., Leonard S.S., Levin E.D., Lukas R.J., Markou A., Marks M.J., McCallum S.E., Parameswaran N., Perkins K.A., Picciotto M.R., Quik M., Rose J.E., Rothenfluh A., Schafer W.R., Stolerman I.P., Tyndale R.F., Wehner J.M., Zirger J.M. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007, 190:269-319.
26. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., Greenberg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999, 19:2987-2995.
27. Parikh V., Ji J., Decker M.W., Sarter M. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci 2010, 30:3518-3530.
28. Paulson J.R., Yang T., Selvaraj P.K., Mdzinarishvili A., Van der Schyf C.J., Klein J., Bickel U., Abbruscato T.J. Nicotine exacerbates brain edema during in vitro and in vivo focal ischemic conditions. J Pharmacol Exp Ther 2010, 332:371-379.
29. Rothman S.M., Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986, 19:105-111.
30. Ryan R.E., Ross S.A., Drago J., Loiacono R.E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 2001, 132:1650-1656.
31. Schurr A. Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr Drug Targets 2004, 5:603-618.
32. Shen H., Lin Z., Lei D., Han J., Ohlemiller K.K., Bao J. Old mice lacking high-affinity nicotine receptors resist acoustic trauma. Hear Res 2011, 277:184-191.
33. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Xue I.C., Piattoni-Kaplan M., Molinari E., Campbell J.E., McKenna D.G., Gunn D.E., Lin N.H., Ryther K.B., He Y., Holladay M.W., Wonnacott S., Williams M., Arneric S.P. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 1997, 283:235-246.
34. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits alpha4 and beta2 messenger RNA expression in postmortem human putamen. Implications for susceptibility to Parkinsonism. Brain Res 1998, 791:186-190.
35. Tyagi E., Agrawal R., Nath C., Shukla R. Inhibitory role of cholinergic system mediated via alpha7 nicotinic acetylcholine receptor in LPS-induced neuro-inflammation. Innate Immun 2010, 16:3-13.
36. Wu L.J., Wu G., Akhavan Sharif M.R., Baker A., Jia Y., Fahey F.H., Luo H.R., Feener E.P., Clapham D.E. The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke. Nat Neurosci 2012, 15:565-573.
37. Yenari M.A., Han H.S. Neuroprotective mechanisms of hypothermia in brain ischaemia. Nat Rev Neurosci 2012, 13:267-278.
38. Yu K.D., Liu Q., Wu J., Lukas R.J. Kinetics of desensitization and recovery from desensitization for human alpha4beta2-nicotinic acetylcholine receptors stably expressed in SH-EP1 cells. Acta Pharmacol Sin 2009, 30:805-817.
39. Zameer A., Kasturirangan S., Emadi S., Nimmagadda S.V., Sierks M.R. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J Mol Biol 2008, 384:917-928.